Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Jun 6;92(12):5491-5.
doi: 10.1073/pnas.92.12.5491.

Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division

Affiliations

Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division

L H Boise et al. Proc Natl Acad Sci U S A. .

Abstract

Growth factors have been defined by their ability to promote the proliferative expansion of receptor-bearing cells. For example, antigen-activated T cells expressing the alpha beta gamma form of the interleukin 2 (IL-2) receptor will proliferate in response to IL-2. In contrast, resting T cells, which express the IL-2 receptor beta and gamma chains, do not proliferate in response to IL-2. We demonstrate that the survival of resting T cells following gamma irradiation is greatly enhanced by pretreatment with IL-2. The radioprotective effect of IL-2 is dose dependent, does not result from the induction of cell proliferation, and does not require expression of the IL-2 receptor alpha chain. Thus, the beta gamma IL-2 receptor expressed on resting T cells can transduce signals that promote cell survival without committing the T cell to undergo cell division. IL-4 and IL-7, but not IL-1, IL-3, or IL-6, were also found to enhance the survival of quiescent T cells following gamma irradiation. Thus, certain growth factor-receptor interactions can serve to maintain cell viability in a manner that is independent of their ability to initiate or maintain cell proliferation. These data may have important implications for the use of growth factors in patients being treated with radiation and/or chemotherapy.

PubMed Disclaimer

References

    1. J Immunol. 1991 May 1;146(9):3049-55 - PubMed
    1. J Exp Med. 1988 Mar 1;167(3):1265-70 - PubMed
    1. Nature. 1991 Oct 31;353(6347):858-61 - PubMed
    1. Cell. 1991 Dec 20;67(6):1033-6 - PubMed
    1. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2165-9 - PubMed

Publication types